Vascular implants – new aspects for in situ tissue engineering. Issue 3 (7th January 2022)

• Record Type: Journal Article
• Authors: Blume, Cornelia; Kraus, Xenia; Heene, Sebastian; Loewner, Sebastian; Stanislawski, Nils; Cholewa, Fabian; Blume, Holger
• Other Names: Beutel Sascha guestEditor.
• Is Part Of: Engineering in life sciences. Volume 22:Issue 3/4(2022)
• Page Start: 344
• Page End: 360
• Publication Date: 2022-01-07
• Subjects: bioreactor design -- tissue engineering -- vascular implants -- 3D printing; Bioengineering -- Periodicals; 660.605
• DOI: 10.1002/elsc.202100100
• Languages: English
• ISSNs: 1618-0240

Abstract

Abstract: Conventional synthetic vascular grafts require ongoing anticoagulation, and autologous venous grafts are often not available in elderly patients. This review highlights the development of bioartificial vessels replacing brain‐dead donor‐ or animal‐deriving vessels with ongoing immune reactivity. The vision for such bio‐hybrids exists in a combination of biodegradable scaffolds and seeding with immune‐neutral cells, and here different cells sources such as autologous progenitor cells or stem cells are relevant. This kind of in situ tissue engineering depends on a suitable bioreactor system with elaborate monitoring systems, three‐dimensional (3D) visualization and a potential of cell conditioning into the direction of the targeted vascular cell phenotype. Necessary bioreactor tools for dynamic and pulsatile cultivation are described. In addition, a concept for design of vasa vasorum is outlined, that is needed for sustainable nutrition of the wall structure in large caliber vessels. For scaffold design and cell adhesion additives, different materials and technologies are discussed. 3D printing is introduced as a relatively new field with promising prospects, for example, to create complex geometries or micro‐structured surfaces for optimal cell adhesion and ingrowth in a standardized and custom designed procedure. Summarizing, a bio‐hybrid vascular prosthesis from a controlled biotechnological process is thus coming more and more into view. It has the potential to withstand strict approval requirements applied for advanced therapy medicinal products.